The stock of Bristol-Myers Squibb Co (BMY) has gone down by -2.44% for the week, with a -18.06% drop in the past month and a -12.68% drop in the past quarter. The volatility ratio for the week is 2.91%, and the volatility levels for the past 30 days are 3.81% for BMY. . The simple moving average for the past 20 days is -11.76% for BMY’s stock, with a -8.24% simple moving average for the past 200 days.
Is It Worth Investing in Bristol-Myers Squibb Co (NYSE: BMY) Right Now?
Moreover, the 36-month beta value for BMY is 0.46. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 4 as “overweight,” 18 as “hold,” and 1 as “sell.”
The public float for BMY is 2.03B and currently, short sellers hold a 1.45% of that float. On April 21, 2025, BMY’s average trading volume was 12.81M shares.
BMY) stock’s latest price update
Bristol-Myers Squibb Co (NYSE: BMY)’s stock price has gone decline by -0.26 in comparison to its previous close of 49.36, however, the company has experienced a -2.44% decrease in its stock price over the last five trading days. zacks.com reported 2025-04-18 that Besides Wall Street’s top -and-bottom-line estimates for Bristol Myers (BMY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Analysts’ Opinion of BMY
Many brokerage firms have already submitted their reports for BMY stocks, with Jefferies repeating the rating for BMY by listing it as a “Buy.” The predicted price for BMY in the upcoming period, according to Jefferies is $70 based on the research report published on December 16, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see BMY reach a price target of $63. The rating they have provided for BMY stocks is “Neutral” according to the report published on December 10th, 2024.
BMY Trading at -14.08% from the 50-Day Moving Average
After a stumble in the market that brought BMY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.26% of loss for the given period.
Volatility was left at 3.81%, however, over the last 30 days, the volatility rate increased by 2.91%, as shares sank -18.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.55% lower at present.
During the last 5 trading sessions, BMY fell by -2.44%, which changed the moving average for the period of 200-days by +19.20% in comparison to the 20-day moving average, which settled at $55.79. In addition, Bristol-Myers Squibb Co saw -12.96% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BMY starting from BOERNER CHRISTOPHER S., who purchase 2,000 shares at the price of $55.05 back on Feb 20 ’25. After this action, BOERNER CHRISTOPHER S. now owns 104,626 shares of Bristol-Myers Squibb Co, valued at $110,096 using the latest closing price.
Hirawat Samit, the EVP,Chief Med.Offr.,Drug Dev. of Bristol-Myers Squibb Co, purchase 1,823 shares at $54.84 during a trade that took place back on Feb 14 ’25, which means that Hirawat Samit is holding 63,932 shares at $100,000 based on the most recent closing price.
Stock Fundamentals for BMY
Current profitability levels for the company are sitting at:
- 0.19 for the present operating margin
- 0.67 for the gross margin
The net margin for Bristol-Myers Squibb Co stands at -0.19. The total capital return value is set at 0.13. Equity return is now at value -39.10, with -9.53 for asset returns.
Based on Bristol-Myers Squibb Co (BMY), the company’s capital structure generated 0.76 points at debt to capital in total, while cash flow to debt ratio is standing at 0.3. The debt to equity ratio resting at 3.13. The interest coverage ratio of the stock is 4.69.
Currently, EBITDA for the company is 3.17 billion with net debt to EBITDA at 12.94. When we switch over and look at the enterprise to sales, we see a ratio of 2.92. The receivables turnover for the company is 4.34for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.25.
Conclusion
To wrap up, the performance of Bristol-Myers Squibb Co (BMY) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
